Literature DB >> 19031099

Management of neutralizing antibodies against beta-IFN in beta-IFN-treated multiple sclerosis patients.

Andrew R Pachner, Jennifer Brady, Israel Steiner, Kavitha Narayan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19031099     DOI： 10.1007/s00415-008-0854-2

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  11 in total

1.  Neutralizing anti-IFN-beta antibodies: how much more evidence do we need to use them in practice?

Authors:  Gavin Giovannoni; Andrew Goodman
Journal:  Neurology       Date:  2005-07-12       Impact factor: 9.910

2.  Neutralizing anti-IFNbeta antibodies: clarity and confusion.

Authors:  A R Pachner
Journal:  Mult Scler       Date:  2007-11       Impact factor: 6.312

3.  The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies.

Authors:  Andrew R Pachner; Donna Dail; Elena Pak; Kavitha Narayan
Journal:  J Neuroimmunol       Date:  2005-09       Impact factor: 3.478

4.  Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies.

Authors:  F Deisenhammer; M Reindl; J Harvey; T Gasse; E Dilitz; T Berger
Journal:  Neurology       Date:  1999-04-12       Impact factor: 9.910

5.  Appearance and disappearance of neutralizing antibodies during interferon-beta therapy.

Authors:  P Soelberg Sorensen; N Koch-Henriksen; C Ross; K M Clemmesen; K Bendtzen
Journal:  Neurology       Date:  2005-05-11       Impact factor: 9.910

6.  Monthly corticosteroids decrease neutralizing antibodies to IFNbeta1 b: a randomized trial in multiple sclerosis.

Authors:  Carlo Pozzilli; Giovanni Antonini; Francesca Bagnato; Caterina Mainero; Valentina Tomassini; Emanuela Onesti; Roberta Fantozzi; Simona Galgani; Patrizio Pasqualetti; Enrico Millefiorini; Maria Spadaro; Frank Dahlke; Claudio Gasperini
Journal:  J Neurol       Date:  2002-01       Impact factor: 4.849

7.  An improved ELISA for screening for neutralizing anti-IFN-beta antibodies in MS patients.

Authors:  Andrew R Pachner
Journal:  Neurology       Date:  2003-11-25       Impact factor: 9.910

8.  Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis.

Authors:  S Malucchi; A Sala; F Gilli; R Bottero; A Di Sapio; M Capobianco; A Bertolotto
Journal:  Neurology       Date:  2004-06-08       Impact factor: 9.910

Review 9.  Measurement of MxA mRNA or protein as a biomarker of IFNbeta bioactivity: detection of antibody-mediated decreased bioactivity (ADB).

Authors:  Andrew R Pachner; Antonio Bertolotto; Florian Deisenhammer
Journal:  Neurology       Date:  2003-11-11       Impact factor: 9.910

10.  MxA gene expression analysis as an interferon-beta bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity.

Authors:  Andrew Pachner; Kavitha Narayan; Nicholson Price; Marie Hurd; Donna Dail
Journal:  Mol Diagn       Date:  2003
View more
  3 in total

1.  Natalizumab in the treatment of multiple sclerosis.

Authors:  Brandon A Brown
Journal:  Ther Clin Risk Manag       Date:  2009-08-03       Impact factor: 2.423

2.  Neutralizing antibodies explain the poor clinical response to interferon beta in a small proportion of patients with multiple sclerosis: a retrospective study.

Authors:  Emilia Sbardella; Valentina Tomassini; Claudio Gasperini; Francesca Bellomi; Luca Ausili Cefaro; Vincenzo Brescia Morra; Guido Antonelli; Carlo Pozzilli
Journal:  BMC Neurol       Date:  2009-10-13       Impact factor: 2.474

3.  Anti-Interferon Alpha Antibodies in Patients with High-Risk BCR/ABL-Negative Myeloproliferative Neoplasms Treated with Recombinant Human Interferon-α.

Authors:  Limei Li
Journal:  Med Sci Monit       Date:  2018-04-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.